The Conversation (0)
Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting
Apr. 15, 2016 08:44AM PST
Genetics Investing
Abeona Therapeutics, Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that President and CEO, Tim Miller, Ph.D will be presenting for the company at the Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting in London, England, …
Abeona Therapeutics, Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that President and CEO, Tim Miller, Ph.D will be presenting for the company at the Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting in London, England, April 16th, 2016 at 10:00 AM.
According to the news:
Abeona announced FDA approval for the Company’s Investigational New Drug Application for ABO-102 (AAV- SGSH), a single treatment strategy for Mucopolysaccharidosis Type IIIA (MPS IIIA). The ABO-102 IND application is now active and enables Nationwide Children’s Hospital (Columbus, OH) to initiate a Phase 1/2 clinical study designed to assess the safety, tolerability and potential efficacy of ABO-102 in children with MPS IIII A.